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Background: A residual risk of cardiovascular disease tends to persist despite standard prevention therapy with
statins. This may stem partly from increased oxidized low-density lipoprotein (LDL) levels. However, how oxidized
LDL can be further reduced beyond statin therapy in high-risk diabetes patients remains unclear. We aimed to
clarify the clinical factors associated with oxidized LDL levels in statin-treated high-risk diabetes patients.
Methods: This cross-sectional observational study included 210 diabetes patients with coronary artery diseases (CAD)
who were treated with statins. We determined serum malondialdehyde-modified LDL (MDA-LDL), LDL cholesterol,
high-density lipoprotein (HDL) cholesterol, triglyceride (TG), remnant lipoprotein cholesterol, hemoglobin (Hb) A1c,
adiponectin, and C-reactive protein (CRP) levels and investigated the factors influencing the MDA-LDL level.
Results: In univariate analysis, the MDA-LDL level was significantly correlated with LDL cholesterol (p < 0.0001), TG
(p < 0.0001), HDL cholesterol (p = 0.017), and adiponectin (p = 0.001) levels but not with age, body mass index, waist
circumference, blood pressure, or HbA1c levels. Even after adjusting for the LDL cholesterol level, the correlations
between the MDA-LDL level and the TG, HDL cholesterol, and adiponectin levels were still significant. Among these
significant factors, multivariate analysis revealed that the MDA-LDL level was independently associated with the LDL
cholesterol, TG, and HDL cholesterol but not with adiponectin levels. The MDA-LDL level was also significantly
associated with the CRP level (p = 0.014) and the remnant lipoprotein cholesterol level (p < 0.0001) independently of
the LDL cholesterol level. The number of metabolic syndrome (MS) components was significantly associated with the
MDA-LDL/LDL cholesterol ratio (p < 0.0001). Furthermore, the use of metformin and α-glucosidase inhibitors was
inversely associated with high MDA-LDL levels (p = 0.033 and 0.018, respectively).
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Conclusion: In statin-treated diabetes patients with CAD, the MDA-LDL level was significantly correlated with TG and
HDL cholesterol levels. Adiponectin level was also significantly associated with the MDA-LDL level, but not independent
of the above-mentioned factors. The management of dyslipidemic MS components, including the use of metformin or
α-glucosidase inhibitors, may be important for reducing the oxidized LDL levels beyond statin therapy in high-risk
diabetes patients.
Keywords: MDA-LDL, Metabolic syndrome, Triglycerides, HDL cholesterol, Adiponectin, Diabetes mellitus,
Coronary artery disease, StatinsBackground
Patients with diabetes mellitus (DM) are at high risk for
death caused by cardiovascular disease and even higher
risk if they have developed coronary artery disease
(CAD) [1]. Rather than coronary intervention, preven-
tion therapy is more crucial for reducing the mortality of
high-risk patients [2]. According to many clinical trials,
it is well established that lowering low-density lipopro-
tein (LDL) levels with statins is an important prevention
strategy for CAD [3,4]. However, even if statins can suc-
cessfully attenuate the LDL levels, the risk of CAD can-
not be eliminated. This residual risk of CAD may
involve an increase in the circulating levels of oxidized
LDL, which plays an important role in the pathogenesis
of atherosclerosis [5,6]. Several studies have demon-
strated an association between the prevalence of CAD
and the oxidized LDL level [7-10]. Furthermore, the oxi-
dized LDL level may be a useful marker for secondary
coronary events in type 2 diabetic patients [11]. Statins
reduce the serum oxidized LDL level via LDL-lowering
and antioxidative effects [12]. However, in addition to
the established prevention therapy with statins, it is un-
clear how oxidized LDL levels can be further reduced in
the high-risk patients with DM.
Patients with metabolic syndrome (MS) are at high
risk for CAD and the related mortality [13]. The associ-
ation between MS and oxidized LDL has recently been
demonstrated [14-16]. Adiponectin, a protein released
exclusively from adipocytes, has anti-diabetic and anti-
atherosclerotic properties [17,18]. Many clinical studies
have demonstrated the predictive value of the plasma
adiponectin level for severe CAD, myocardial infarction,
and mortality [19-21]. In obese individuals, circulating
adiponectin levels are decreased [22], which may partly
explain the molecular basis of obesity-associated insulin
resistance and atherosclerosis. Furthermore, a low adipo-
nectin level is associated with a high triglyceride (TG)
level [23], a low high-density lipoprotein (HDL) choles-
terol level [24,25], and hypertension [26], suggesting the
involvement of adiponectin in the pathogenesis of MS
[27]. Systemic oxidative stress levels determined by serum
and urinary lipid peroxidation parameters are inversely
correlated with serum adiponectin levels in obese people[28]. Moreover, a low serum adiponectin level is associ-
ated with a high level of circulating oxidized LDL [29].
However, it remains unclear whether MS and adiponectin
levels are still significantly associated with oxidized LDL
levels under statin treatment in high-risk DM patients.
Malondialdehyde-modified LDL (MDA-LDL) is recog-
nized as a surrogate marker of oxidized LDL, and it has
been suggested that circulating MDA-LDL levels could
be a useful indicator for the identification of patients
with CAD [7]. In this study, we investigated the clinical
factors associated with MDA-LDL levels and evaluated
the significance of the MS components and serum adi-
ponectin levels in statin-treated DM patients with CAD.
Moreover, we investigated whether any medications
affect the MDA-LDL levels in these subjects. Identifying
factors that significantly affect the MDA-LDL level
should help establish a strategy that can further reduce
LDL oxidization in addition to statin therapy, leading to




We conducted a cross-sectional observational study of
237 DM patients with CAD who underwent coronary
angiography or coronary artery computed tomography
between 2010 and 2011. All subjects were treated with
statins for secondary prevention. We analyzed 210 pa-
tients after excluding those who had uncontrolled diabetes
with hemoglobin (Hb) A1c > 10.0%, severe hypertriglyc-
eridemia with serum TG> 400 mg/dL, chronic kidney dis-
ease with serum creatinine > 2.0 mg/dL, or inflammatory
disease with C-reactive protein (CRP) > 3.0 mg/dL. In-
formed consent was obtained from all subjects. This study
protocol was approved by the Ethics Committee of Kure
Medical Center.
Laboratory measurements
Venous blood was drawn from all subjects after an over-
night fast. Serum levels of total cholesterol, TG, and
HDL cholesterol were determined enzymatically (Sekisui
Medical Co., Ltd., Tokyo, Japan). Serum MDA-LDL
levels were measured by a sandwich enzyme-linked
Table 1 Subject characteristics
N 210
Age ─ years 70.6 ± 8.7
Male sex ─ no. (%) 136 (64.7)
Morphometric findings
Body mass index ─ kg/m2 24.6 ± 4.1
Waist circumference ─ cm 88.6 ± 10.5
Blood pressure
Systolic ─ mmHg 133.5 ± 19.6
Diastolic ─ mmHg 73.9 ± 13.5
Laboratory measurements
Serum creatinine ─ mg/dL 0.9 ± 0.2
Total cholesterol ─ mg/dL 166.4 ± 31.7
Triglycerides ─ mg/dL
Median (interquartile range) 105 (77–143)
HDL cholesterol ─ mg/dL 50.1 ± 13.7
LDL cholesterol ─ mg/dL 92.6 ± 23.0
MDA-LDL ─ U/L 99.0 ± 39.0
Hemoglobin A1c ─ % 6.9 ± 1.0
Adiponectin ─ μg/dL
Median (interquartile range) 13.3 (8.5 − 24.1)




Ca channel blockers 85 (40.5)
Metformin 84 (40.0)
Pioglitazone 79 (37.6)
α-Glucosidase inhibitors 70 (33.3)
Sulfonylurea 61 (29.0)
Insulin therapy 37 (17.6)
Phenylalanine derivatives 14 (6.7)
DPP4 inhibitors 15 (7.1)
EPA 9 (4.3)
Ezetimibe 1 (0.5)
Values represent means ± SD unless indicated otherwise.
Abbreviations: ARB angiotensin II receptor blocker, ACE-I angiotensin-converting
enzyme inhibitor, DPP4 dipeptidyl peptidase-4; EPA eicosapentaenoic acid, HDL
high-density lipoprotein, LDL low-density lipoprotein, MDA-LDL malondialdehyde-
modified LDL.
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Tokyo, Japan) with intra-assay coefficients of variation
(CV) of 4.95–7.58% and inter-assay CV of 3.63–7.60%.
The HbA1c value was estimated as a National Glycohe-
moglobin Standardization Program-equivalent percent-
age calculated using the following formula: HbA1c (%) =
1.02 × HbA1c (Japan Diabetic Society, JDS) (%) + 0.25
[30]. Serum LDL cholesterol levels were calculated using
the Friedewald formula. The serum concentration of
total adiponectin was measured using a sandwich ELISA
system (human adiponectin ELISA kit; Otsuka, Tokushima,
Japan). The serum CRP levels were measured using a latex
agglutination method (Sekisui Medical, Tokyo, Japan).
The serum levels of remnant lipoprotein cholesterol were
determined using a homogenous assay (RemL-C assay;
Kyowa Medex, Tokyo, Japan) [31].
Definition of DM and MS
DM patients were defined according to the Japanese cri-
teria [30] and/or prior use of anti-diabetic medication. The
components of MS other than high plasma fasting glucose
(all patients had DM) were defined according to the
Japanese criteria [32] as follows: (1) waist circumference
≥ 85 cm for men or ≥ 90 cm for women; (2) elevated
serum TG ≥ 150 mg/dL; (3) reduced serum HDL choles-
terol < 40 mg/dL; and (4) elevated systolic blood pressure
≥ 130 mmHg and/or diastolic blood pressure ≥ 85 mmHg
and/or prior use of antihypertensive medication.
Statistical analyses
Data are expressed as mean ± standard deviation (SD).
Single and multiple regression analyses were performed
to evaluate the association between MDA-LDL levels
and the indicated variables. Analysis of variance
(ANOVA) with Tukey-Kramer’s honestly significant dif-
ference test was used to evaluate the association between
the number of MS components and the MDA-LDL/LDL
cholesterol ratios. A multivariable logistic model was
used to assess the association between a high MDA-LDL
level and the indicated medications. Statistical analyses
were performed using JMP for Windows (version 9; SAS
Institute, Cary, NC). Statistical significance was defined
by a p value of <0.05.
Results
Subject characteristics
The characteristics of the subjects and the medications
prescribed are shown in Table 1. Because all subjects
were treated with statins, the average LDL cholesterol
was as low as 92.6 mg/dL. The statins used were atorva-
statin 5–20 mg (37% of patients), pravastatin 5–20 mg
(27%), rosuvastatin 2.5–10 mg (26%), pitavastatin 2–
3 mg (7%), simvastatin 5–10 mg (2%), and fluvastatin
20 mg (1%). Other anti-hyperlipidemic agents wereprescribed in a small number of patients: ezetimibe for 1
patient and eicosapentaenoic acid (EPA) for 9 patients.
The mean HbA1c level was 6.9%.
Associations between the MDA-LDL level and various risk
factors
The MDA-LDL level was significantly correlated with the
levels of LDL cholesterol, TG, HDL cholesterol, and adi-
ponectin (p < 0.0001, p < 0.0001, p = 0.017, and p = 0.001,
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waist circumference, blood pressure, or creatinine or
HbA1c levels in single regression analysis (Table 2). Even
after adjusting for the LDL cholesterol level, the MDA-
LDL level was significantly correlated with the levels of
TG, HDL cholesterol, and adiponectin (p < 0.0001, p <
0.0001, and p = 0.002, respectively) (Figure 1). Multiple re-
gression analysis revealed that the levels of LDL choles-
terol, HDL cholesterol, and TG were independently
associated with the MDA-LDL level (Table 3, model 1).
The adiponectin level, however, was not significantly asso-
ciated with the MDA-LDL level in this analysis (Table 3,
model 1).
To understand in more detail the basis of the associ-
ation between the MDA-LDL and TG levels, we investi-
gated the level of remnant lipoprotein cholesterol. The
remnant lipoprotein cholesterol level was significantly
correlated with the TG level with a very high correlation
coefficient (r = 0.940) and the LDL cholesterol level with a
relatively low correlation coefficient (r = 0.246) (Figure 2A
and B), suggesting that the remnant lipoproteins could be
the major lipoproteins carrying TG in the fasting state
upon statin treatment. Furthermore, the remnant lipopro-
tein cholesterol level was significantly correlated with the
MDA-LDL level independently of the LDL cholesterol
level in a multiple regression model (Figure 2C).Association between the MDA-LDL/LDL cholesterol ratio
and the number of MS components
The number of MS components present was signifi-
cantly associated with the MDA-LDL/LDL cholesterol
ratio (p < 0.0001) (Figure 3). Patients with ≥4 of the 5
MS component factors had a significantly higher MDA-
LDL/LDL cholesterol ratio than those with fewer factorsTable 2 Relationship between the level of MDA-LDL and
various parameters in univariate analyses
r p
Age 0.010 0.887
Body mass index −0.023 0.739
Waist circumference 0.025 0.724
Systolic blood pressure 0.075 0.281
Creatinine 0.036 0.600
Hemoglobin A1c 0.068 0.330
LDL cholesterol 0.458 <0.0001
Triglycerides* 0.435 <0.0001
HDL cholesterol −0.164 0.017
Adiponectin* −0.227 0.001
Abbreviations: HDL high-density lipoprotein, LDL low-density lipoprotein,
MDA-LDL malondialdehyde-modified LDL.
Statistical analyses were performed using simple regression.
*Log-transformed values were subjected to statistical analyses.(p < 0.05 for 4 vs. 1, 2, or 3 MS components; p < 0.001
for 5 vs. 1, 2, or 3 MS components).
Association between a high MDA-LDL level and
inflammation
Because inflammation plays a pivotal role in the patho-
genesis of both MS and atherosclerosis, we investigated
the association between CRP and MDA-LDL levels. A
high CRP level of ≥ 0.2 mg/dL was significantly associ-
ated with a high MDA-LDL level (defined by a median
value of > 91 U/L), compared with a low CRP level of
< 0.1 mg/dL (Table 4). This association remained signifi-
cant even after adjusting for the LDL cholesterol level
(Table 4). However, this significance was diminished by
adjusting for both LDL cholesterol and TG levels and was
eliminated after adjusting for LDL cholesterol, TG, and
HDL cholesterol levels (Table 4).
Association between a high MDA-LDL level and
medications combined with statins
In a multivariate logistic analysis adjusted for LDL chol-
esterol, TG, HDL cholesterol, and adiponectin levels, we
found, among the medications used in combination with
statins, that the use of metformin and α-glucosidase in-
hibitors (α-GIs) was inversely associated with a high
MDA-LDL level (defined by a median value of > 91 U/L)
(Table 5). Conversely, the associations of LDL choles-
terol, TG, and HDL cholesterol with MDA-LDL
remained significant in another multivariate model even
after adjustment for the use of metformin and α-GIs
(Table 3, model 2).
Discussion
In this study, the level of MDA-LDL was significantly
correlated with the levels of TG, HDL cholesterol, and
adiponectin, independent of the LDL cholesterol level, in
statin-treated DM patients with CAD. However, there
was no significant association between the level of adi-
ponectin and the level of MDA-LDL when the regres-
sion was adjusted for the levels of LDL cholesterol, TG,
and HDL cholesterol. An increasing number of MS
components resulted in a higher MDA-LDL/LDL chol-
esterol ratio. Among the medications used in combin-
ation with statins, the use of metformin and α-GIs was
inversely associated with a high MDA-LDL level in
multivariate logistic analysis.
This study revealed that TG and HDL cholesterol were
significantly correlated with MDA-LDL levels independ-
ent of the LDL cholesterol level in statin-treated high-
risk DM patients. An increased TG level and decreased
HDL cholesterol level are observed due to insulin resist-
ance, and hence, they are recognized as dyslipidemic
components of MS. The prolonged presence of in-































































Figure 1 Correlations between the malondialdehyde-modified
low-density lipoprotein (MDA-LDL) level and associated factors
after adjusting for LDL cholesterol levels. The MDA-LDL level
(U/L) was significantly correlated with the levels of log-transformed
triglycerides (A), high-density lipoprotein (HDL) cholesterol (mg/dL)
(B), and log-transformed adiponectin (C) with the indicated partial
correlation coefficient (β) and p value. Statistical analyses were
performed by multiple regression models adjusted for LDL cholesterol
level.
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study revealed the significant association between the levels
of MDA-LDL and remnant lipoprotein cholesterol. Activa-
tion of lectin-like oxidized LDL receptor-1 by remnant
lipoprotein particles induces nicotinamide adenine di-
nucleotide phosphate (NADPH) oxidase-dependent pro-
duction of superoxide in endothelial cells [35], which
may explain the significant association between LDL
oxidation and remnant lipoproteins rich in TG. More-
over, HDL protects against the oxidation of LDL [36].
Taken together, these results might explain the close as-
sociation between oxidized LDL and the dyslipidemic
components of MS. Holvoet et al. demonstrated the as-
sociation between various features of MS and oxidized
LDL in well-functioning elderly people [14]. Our study,
however, indicated that in statin-treated DM patients,
the level of MDA-LDL was associated with the dyslipid-
emic components of MS but not with other features of
MS, including blood pressure, waist circumference, or
the level of HbA1c (instead of fasting glucose). Never-
theless, patients with ≥4 of the 5 MS factors had a sig-
nificantly higher MDA-LDL/LDL cholesterol ratio than
those with fewer factors. This suggests that the add-
itional presence of hypertension and/or abdominal obes-
ity can somehow aggravate the oxidation of LDL. These
findings also suggest that accumulation of these MS-
constituting factors should be attenuated to reduce theTable 3 Impact of LDL cholesterol, triglycerides, HDL
cholesterol, and adiponectin on the level of MDA-LDL in
the multivariate analyses
Model 1 Model 2
β p β p
LDL cholesterol 0.452 <0.0001 0.444 <0.0001
Triglycerides* 0.317 <0.0001 0.318 <0.0001
HDL cholesterol −0.137 0.049 −0.139 0.048
Adiponectin* −0.049 0.481 −0.032 0.648
Abbreviations: HDL high-density lipoprotein, LDL low-density lipoprotein,
MDA-LDL malondialdehyde-modified LDL.
In model 1 (R2 = 0.361), LDL cholesterol, triglycerides, HDL cholesterol, and
adiponectin were included as the variables in the multiple regression analysis.
In model 2 (R2 = 0.365), medications (metformin and α-glucosidase inhibitors)
were added to the variables for the model 1 analysis.
*Log-transformed values were subjected to statistical analyses.
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Figure 2 Associations of the remnant lipoprotein cholesterol
level with the levels of triglycerides, low-density lipoprotein
(LDL) cholesterol, and malondialdehyde-modified LDL
(MDA-LDL). A and B, The remnant lipoprotein cholesterol level
(mg/dL) was significantly correlated with the levels of triglycerides
(mg/dL) (A) and LDL cholesterol (mg/dL) (B) with the indicated
correlation coefficient (r) and p value in simple regression analyses.
C, The remnant lipoprotein cholesterol level (mg/dL) was significantly
correlated with the MDA-LDL level (U/L) with the indicated partial
correlation coefficient (β) and p value in a multiple regression model
adjusted for LDL cholesterol level.
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DM patients.
Inflammation plays a pivotal role in the progression of
atherosclerosis. CRP ≥ 0.2 mg/dL is significantly associ-
ated with the incidence of cardiovascular events [37,38].
The current data indicated that a high CRP level of
≥0.2 mg/dL was significantly associated with a high level
of MDA-LDL independently of LDL cholesterol. On the
other hand, additional adjustment for TG and HDL
cholesterol levels eliminated the significance of the asso-
ciation between CRP and MDA-LDL levels, suggesting
that the inflammation may affect LDL oxidation, pos-
sibly through the dyslipidemic changes of MS.
We previously demonstrated that oxidative stress was
closely associated with a low adiponectin level [28]. Adi-
ponectin production from adipocytes was suppressed by
reactive oxygen species but reversed by the addition of
an antioxidant agent [28]. Treating KKAy obese mice
with apocynin, an NADPH oxidase inhibitor, prevented
the reduction in adiponectin level by suppressing oxidative
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Figure 3 Association between the malondialdehyde-modified
low-density lipoprotein (MDA-LDL)/LDL cholesterol (C) ratio
and the number of metabolic syndrome (MS) components. The
MDA-LDL/LDL-C ratios were compared in patients with the indicated
number of MS components. Data are expressed as means ± SD.
Statistical analyses were performed by analysis of variance with
Tukey-Kramer’s honestly significant difference test. *, p < 0.05 vs. 1, 2,
or 3; **, p < 0.001 vs. 1, 2, or 3.
Table 4 Association between CRP levels and high MDA-LDL level in univariate and multivariate logistic analyses
CRP concentration, mg/dL
<0.1 0.1–0.2 ≥0.2 p*
Univariate, OR (95% CI) 1 1.77 (0.89–3.55) 3.40 (1.54–8.02) 0.006
Multivariate, OR (95% CI)
Adjusted for LDL-C 1 1.43 (0.68–3.01) 3.44 (1.49–8.45) 0.014
Adjusted for LDL-C, TG 1 1.08 (0.49–2.35) 2.74 (1.14–6.95) 0.071
Adjusted for LDL-C, TG, HDL-C 1 0.95 (0.42–2.09) 2.41 (0.98–6.20) 0.124
Abbreviations: CI confidence interval, CRP C-reactive protein, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, MDA-LDL
malondialdehyde-modified LDL, OR odds ratio; TG triglycerides.
Univariate and multivariate logistic analyses with an adjustment for the indicated parameters were performed. A high MDA-LDL level was defined by a median
value of >91 U/L.
*Likelihood ratio test for trend.
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against damage induced by oxidative stress in the vascular
walls and myocardium [39,40]. Thus, adiponectin is likely
to be closely linked to oxidative stress. A low adiponectin
level was inversely associated with the oxidized LDL level
[29]. Similarly, in our study, the level of adiponectin was
significantly correlated with the MDA-LDL level in the re-
gression analysis adjusted for the LDL cholesterol level.
However, this correlation was not significant after we ad-
justed for the levels of TG and HDL cholesterol, possibly
because the level of adiponectin is negatively correlated
with the TG level and positively correlated with the HDL
cholesterol level [27]. Collectively, the relationship betweenTable 5 Multivariate logistic analysis of the relationship
between medications used with statins and high
MDA-LDL level
Adjusted OR (95% CI) p
ACE-Is or ARBs 1.29 (0.61–2.78) 0.508
β-Blockers 1.04 (0.51–2.12) 0.923
Ca channel blockers 1.23 (0.62–2.45) 0.548
Metformin 0.48 (0.24–0.94) 0.032
Pioglitazone 0.61 (0.28–1.28) 0.190
α-Glucosidase inhibitors 0.43 (0.21–0.87) 0.018
Sulfonylurea 1.65 (0.76–3.66) 0.205
Insulin therapy 0.51 (0.21–1.20) 0.124
Other variables
LDL cholesterol 241.6 (22.0–3289.8)* <0.0001
Triglycerides 12.95 (2.02–93.09)* 0.007
HDL cholesterol 0.10 (0.00–0.98)* 0.048
Adiponectin 1.18 (0.19–7.12)* 0.859
Abbreviations: ACE-I angiotensin-converting enzyme inhibitor, ARB angiotensin
II receptor blocker, CI confidence interval; HDL high-density lipoprotein,
LDL low-density lipoprotein, MDA-LDL malondialdehyde-modified LDL,
OR odds ratio.
Multivariate logistic regression analysis was performed with an adjustment for
all indicated medicines and the levels of LDL cholesterol, triglycerides, HDL
cholesterol, and adiponectin. A high MDA-LDL level was defined by a median
value of >91 U/L.
*Range OR (95% CI).the adiponectin and oxidized LDL levels may be influenced
by the TG and HDL cholesterol levels.
Keaney et al. demonstrated that obesity was associated
with systemic oxidative stress as assessed by the level of
urinary 8-epi-prostaglandin F2α (PGF2α) [41]. Similarly,
we demonstrated that the level of serum thiobarbituric
acid reactive substance and urinary 8-epi-PGF2α were
positively correlated with BMI independent of diabetes
in humans [28]. However, in the present study, the
MDA-LDL level was not significantly associated with
BMI or waist circumference despite a significant associ-
ation with obesity-related factors such as TG, HDL chol-
esterol, and adiponectin levels. Both MDA-LDL and
lipid peroxidation parameters indicate the level of oxida-
tive stress. However, they may have different associations
with clinical parameters such as LDL cholesterol level or
BMI because of their different origins.
In the present study, the use of metformin was in-
versely associated with a high MDA-LDL level, inde-
pendent of LDL cholesterol, TG, and HDL cholesterol
levels. Metformin reduces the synthesis of hepatic very-
low-density lipoprotein and the production of glucose,
which is mediated by 5’-adenosine monophosphate-
activated protein kinase [42], and leads to increased in-
sulin sensitivity and reduction in the plasma TG levels.
This might partly contribute to the reduction in MDA-
LDL levels, although the precise mechanism remains to
be clarified. Similarly, the use of α-GIs was inversely as-
sociated with a high MDA-LDL level. The α-GIs report-
edly suppress oxidative stress in the vascular wall by
suppressing postprandial hyperglycemia [33,43], which
might explain the reduction of MDA-LDL. Despite in-
creasing the circulating levels of adiponectin [44,45] as
well as several antioxidative enzymes [46-48], the use of
pioglitazone was not significantly associated with the
MDA-LDL level in this analysis. The antioxidative ac-
tions of pioglitazone might not be as effective as metfor-
min or α-GIs in suppressing LDL oxidation. Further
investigation of this issue is required. Among various
anti-diabetic agents, metformin and α-GIs have been
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diovascular disease in large-scale clinical trials [49,50].
Importantly, they suppress weight gain [49,50]. An im-
provement in insulin resistance and postprandial hyper-
glycemia with suppression of weight gain may be
important for reducing LDL oxidation, which should
contribute to the prevention of cardiovascular events.
When the 9 patients who had taken EPA were ex-
cluded from the univariate analysis, the correlations of
the LDL cholesterol, TG, HDL cholesterol, and adipo-
nectin levels with the MDA-LDL level remained sig-
nificant. However, in the multivariate analysis, the
association of HDL cholesterol with MDA-LDL was
weakened from p = 0.049 to p = 0.065, suggesting that
EPA might affect the MDA-LDL level, possibly through
an influence on TG and HDL cholesterol levels. There-
fore, further analysis in a large population is required to
resolve this issue.
This study had several limitations. The subjects in this
study were relatively elderly patients (mean age,
70.6 years), and any differences with respect to age are
unknown. In addition, this was a cross-sectional obser-
vational study conducted in a single center. Multicenter
prospective cohort studies and randomized controlled
trials are essential to determine the clinical determinants
of oxidized LDL and effective medications for reducing
LDL oxidation.Conclusion
DM patients with CAD are at very high risk for cardio-
vascular events. Hence, they require a risk-reducing
strategy beyond the standard prevention therapy with
statins. In these patients treated with statins, the circu-
lating MDA-LDL levels were significantly correlated
with the TG and HDL cholesterol levels. Adiponectin
levels were also significantly correlated with MDA-LDL
levels, but not independent of TG and HDL cholesterol.
Furthermore, treatment with metformin or α-GIs might
be associated with a reduction in MDA-LDL levels. Col-
lectively, this study suggests that in addition to statin
therapy, the management of dyslipidemic MS compo-
nents, including use of metformin or α-GIs, is important
for reducing the oxidization of LDL and, ultimately, the
risk of cardiovascular events in high-risk DM patients.
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